Our technology platform
The CER T cell platform represents a novel class of engineered T cells that offer synergies with targeted cancer therapies
Multimodal approach to optimize cellular immunotherapy
We are constructing multifunctional engineered CER T cells with the potential to be deployed against a broad range of hematologic and solid tumors, and potentially other diseases.
Engineered cellular therapies represent a new standard of care for patients with relapsed or refractory hematologic cancers; however, the remarkable success of these therapies has not yet translated to solid tumors. In addition, currently available cellular therapies can have notable toxicity and fewer than half of all responders have a durable response beyond 2 years. Further, current cell therapies require the existence of specific tumor-associated antigens, which is particularly challenging with solid tumors. The complex interplay between diverse molecular and immune processes that govern resistance to cellular-based therapies compels a multimodal approach.
Multifunctional CER T cells offer the potential for improved patient outcomes by synergizing with a variety of targeted therapies with applicability to a broad spectrum of diseases, including oncology as well as other conditions.
CERo’s platform provides a distinct approach to other immune-based therapies. The platform has the potential to recognize broad tumor types, and, by combining the body’s own natural clearance machinery with enhanced T-cell cytotoxic effects and APC-like capabilities, CER T cells can amplify the body’s anti-tumor immune response.
The novel mechanism of action of CERo’s platform presents multiple opportunities to leverage synergies between CER T cells and existing treatment approaches, which may result in more durable and potentially curative outcomes for patients across multiple indications.
CERo’s multimodal strategy rationally combines therapies:
- Combinations with targeted small molecules or other targeted agents
- Single engineered dual targeting CER/CAR T cell
In both approaches, the mechanism of action involves CER-directed cell killing and CER-induced endogenous secondary immune responses, potentially leading to an enhanced treatment response.
Our lead program utilizes a standard-of-care targeted small molecule inhibitor to induce the stress ligand on the tumor, allowing the CER T cell to specifically target the tumor.